Related Experiment Video
Updated: Sep 19, 2025

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Late Preterm Antenatal Corticosteroids in Pregestational and Gestational Diabetic Pregnancies
Lylach Haizler-Cohen1, Maria C Alzamora1, Nicole R Legro1
1Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, MedStar Washington Hospital Center, Washington, District of Columbia.
Insights
Late preterm antenatal corticosteroids (ACS) in diabetic pregnancies did not increase neonatal hypoglycemia or improve overall respiratory issues. However, a complete ACS course did reduce the need for respiratory support in some cases.
Area of Science:
- Maternal-Fetal Medicine
- Neonatology
- Endocrinology
Background:
- Late preterm birth presents risks for neonates, particularly those exposed to maternal diabetes.
- Antenatal corticosteroids (ACS) are used to mature fetal lungs but their role in diabetic pregnancies during the late preterm period is debated.
- Neonatal hypoglycemia and respiratory complications are significant concerns in infants born to mothers with pregestational diabetes mellitus (PGDM) and gestational diabetes mellitus (GDM).
Purpose of the Study:
- To evaluate the association between late preterm antenatal corticosteroids (ACS) administration and neonatal hypoglycemia.
- To assess the impact of late preterm ACS on respiratory complications in neonates born to mothers with PGDM and GDM.
- To explore the influence of diabetes type and glycemic control on these associations.
Main Methods:
- Multi-center retrospective cohort study (2016-2022) including pregnant individuals with PGDM or GDM in the late preterm period.
- Primary outcome: neonatal hypoglycemia. Secondary outcomes: composite respiratory morbidity, NICU admission, length of NICU stay, neonatal death.
- Multivariable regression models adjusted for admission indication, gestational age, and birth weight; stratified analyses by diabetes type, ACS completion, and glycemic control for PGDM.
Main Results:
- No significant difference in neonatal hypoglycemia or composite respiratory morbidity between ACS and non-ACS groups in either PGDM or GDM subgroups.
- A complete course of late preterm ACS was associated with reduced supplemental oxygen use, mechanical ventilation, and respiratory distress syndrome.
- In PGDM pregnancies, neonatal outcomes did not differ between ACS and non-ACS groups, irrespective of glycemic control.
Conclusions:
- Late preterm ACS administration in diabetic pregnancies is not associated with increased neonatal hypoglycemia or improved composite respiratory morbidity.
- A complete course of late preterm ACS may offer respiratory benefits, specifically reducing the need for respiratory support.
- Maternal glycemic control does not appear to modify neonatal outcomes related to late preterm ACS use in diabetic pregnancies.
Abstract:
This study aims to evaluate the association between late preterm antenatal corticosteroids (ACS) administration and the incidence of hypoglycemia and respiratory complications in neonates born to individuals with pregestational diabetes mellitus (PGDM) and gestational diabetes mellitus (GDM).Multi-center retrospective cohort study between 2016 and 2022. Pregnant people with PGDM or GDM who presented in the late preterm period with concern for preterm delivery were included. The indication for admission was classified as preterm labor, preterm prelabor rupture of membranes, poorly controlled diabetes, or other maternal/fetal indications. Exclusion criteria included multifetal gestations, fetal anomalies, stillbirths, prior course of ACS, or no anticipation for delivery in the next 7 days. The primary outcome was neonatal hypoglycemia. Secondary outcomes included composite respiratory morbidity, composite nonrespiratory morbidity, neonatal intensive care unit (NICU) admission, length of NICU stay, and neonatal death. Multivariable regression models were used to calculate the odds ratio and 95% confidence intervals for the outcomes after adjusting for an indication for admission, gestational age at delivery, and neonatal birth weight. Outcome data were then stratified by diabetes type (PGDM vs. GDM) and completion status of the ACS course (partial vs. complete). For PGDM pregnancies, outcome data were additionally stratified by glycemic control.In the study period, 453 patients (126 with PGDM and 327 with GDM) were included. Of those, 265 (58.5%) received ACS, and 188 (41.5%) did not. There were no significant differences in neonatal hypoglycemia and composite respiratory morbidity between the ACS and non-ACS groups, including in the subgroup analysis of PGDM and GDM pregnancies. However, late preterm ACS was associated with reductions in supplemental oxygen use, mechanical ventilation, and respiratory distress syndrome when a complete course of ACS was administered. In PGDM pregnancies, neonatal outcomes did not differ between the ACS and non-ACS groups, regardless of glycemic control.Late preterm ACS administration in diabetic pregnancies was not associated with increased neonatal hypoglycemia or improvements in composite respiratory morbidity. · Late preterm steroids in diabetic pregnancies are not associated with neonatal hypoglycemia.. · Composite respiratory morbidity is not improved in this setting.. · Glycemic control does not impact neonatal outcomes with late preterm steroid use..
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Adrenergic Antagonists: ɑ and β-Receptor Blockers

